Quezada Lab
@QuezadaLab
Followers
1K
Following
188
Media
29
Statuses
321
Immune Regulation and Tumour Immunotherapy Group led by @squezadd, based at the Cancer Institute of University College of London, UCL.
London, England
Joined September 2018
RT @drclaireroddie: š§¬ Join us Friday 19th Sept for CART Autoimmunity Symposium in Central London š§¬ Guest speakers from Erlangen & Hamburg oā¦.
hartleytaylor.co.uk
0
7
0
RT @ACIR_org: Depletion of Tregs with a non-IL-2-blocking anti-CD25Ā enhanced antitumor responses in brain tumors and synergized with anti-ā¦.
0
2
0
RT @jsoriamd: CHIP is a common, age-related condition where mutated blood stem cells expand without causing blood disorders. CHIP raises thā¦.
0
44
0
Regulatory TĀ cell depletion promotes myeloid cell activation and glioblastoma response to anti-PD1 and tumor-targeting antibodies: Amazing collaboration led by @CR_UK funded @QuezadaLab @galvez_cancino @uclcancer and colleagues!.
cell.com
Glioblastoma is an aggressive subtype of glioma that responds poorly to immune checkpoint blockade (ICB). Galvez-Cancino et al. demonstrate that Treg cell depletion using a non-IL-2 blocking antibo...
6
16
61
RT @EJohnWherry: This is exactly right. Gutting the NIH will lead to a rapid labor shortage and all these jobs going overseas.
0
19
0
RT @CharlesSwanton: Many congratulations ā¦@FAndreMDā© ā¦@cncurtisā© on the Susan G Komen awards - a great recognition for all your discoveriesā¦.
0
1
0
RT @CRUKCOLcentre: Happy Post Doc Appreciation Week! Our facilities are used by Post Docs at @uclcancer, @kingsmedicine, @QMBCI and @TheCriā¦.
0
1
0
Looking fwd to a great conference!!!.
Good and Bad CD4 T-cell Help:.Cornelis JM Melief, Sergio Quezada, and Robert D. Schreiber will address this topic in a plenary session at the AACR Special Conference on Tumor Immunology and Immunotherapy (October 18-21, Boston). #AACRtii24 @squezadd
0
2
9
Tremendous line up of speakers! Come join us in Boston!.
Submit an abstract by August 5 for the AACR Special Conference on Tumor Immunology and Immunotherapy (October 18-21, Boston), chaired by Yvonne Y. Chen, Sergio Quezada, Robert D. Schreiber, and Fernando Vidal-Vanaclocha. Learn more:.#AACRtii24 @squezadd
0
2
6
Great collaboration with @Marcrmansour @samuels_yardena @SwantonLab @SineRekerHAdrup @uclcancer and @achillestx funded by @EUhorizon2020.
Really happy to share a link to our most recent preprint: In it we describe the development of a state-of-the-art immunogenicity predictor, laying the necessary foundation for the @AgDecod DECOD-Ag program.
0
2
13
Really happy to share a link to our most recent preprint: In it we describe the development of a state-of-the-art immunogenicity predictor, laying the necessary foundation for the @AgDecod DECOD-Ag program.
biorxiv.org
Neoantigen immunogenicity prediction is a highly challenging problem in the development of personalised medicines. Low reactivity rates in called neoantigens result in a difficult prediction scenario...
0
3
28
RT @NatureRevCancer: DonĀ“t miss this Review summarizing the different antibody-based approaches for targeting cancer cells including #Checkā¦.
0
144
0
RT @squezadd: Absolutely honoured to be elected Fellow of the Academy of Medical Sciences together with amazing ā¦@uclā© colleagues!! Thanksā¦.
ucl.ac.uk
Four UCL scientists have been elected Fellows of the Academy of Medical Sciences in recognition of their exceptional contributions to the study of rheumatology, neurobiology, immunotherapy and
0
12
0
RT @CRUKCOLcentre: Today is #InternationalWomensDay. We are proud to support the many women scientists, students and technical staff at theā¦.
0
8
0
RT @sitcancer: We can't wait to see you Dr. Delgoffe! Thanks for your leadership in bringing this awesome event to fruition! See everyone Sā¦.
0
1
0
RT @evan_foundation: While in London, Gavin had the privilege of rounding our āTreats & Treasures Trolleyā on the onc floor at @GreatOrmondā¦.
0
1
0
RT @CRUKCOLcentre: Proud to announce Team MATCHMAKERS has been one of the 5 successful @CancerGrand. @squezadd @uclcancer is part of the Teā¦.
0
2
0
2/2 Our global team will be pooling our cancer immunology and structural biology knowledge, computer science expertise and high-throughput method development to understand and predict how T cells recognise tumours. Very excited to get started!.
0
0
7
We are so proud and honoured to be part of the incredible #MATCHMAKERS team with the challenge to decipher the T-cell receptor cancer-recognition code. This grand challenge has huge potential to impact the future development of novel therapeutics for cancer! .1/2-.
š¢ Announcing five new global #CancerGrandChallenges teams! š¢. We're thrilled to announce five new teams, each receiving up to $25m over five years to tackle some of cancer's toughest challenges. Meet the teams: @CR_UK @theNCI
4
4
56